Information Provided By:
Fly News Breaks for November 7, 2019
Nov 7, 2019 | 08:46 EDT
Baird analyst Jeff Johnson raised his price target on DexCom to $240 from $195 following strong Q3 results. The analyst noted revenues easily beat the Street and management raised guidance which he believes could drive sustainable upward momentum for the stock as Libre concerns have faded, G7's launch is creeping closer, and the power of pharmacy access is increasingly being felt. Johnson reiterated his Outperform rating on DexCom shares.
News For DXCM From the Last 2 Days
There are no results for your query DXCM